ClinicalTrials.gg
Not yet recruitingNCT07860788Updated Oct 6, 2026

TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years

An interventional study of TRIDERM D.S. Crema Normalizzante in Cradle Cap and Seborrheic Dermatitis, sponsored by ICIM International S.r.l.. Not yet recruiting at 1 site in Italy. Open to participants aged 0 Years to 3 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by ICIM International S.r.l. · Not applicable, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
0 Years to 3 Years
Sex
All
01

Study summary

This clinical study aims to evaluate the effects of using the cosmetic product TRIDERM D.S. Crema Normalizzante in children aged 0 to 3 years with neonatal hyperseborrhea ("cradle cap"), potentially associated with manifestations of mild-to-moderate seborrheic dermatitis. The study will assess whether use of the product is associated with an improvement in the clinical signs of the condition, particularly scaling and erythema, and will evaluate its cutaneous tolerability. Caregiver-perceived improvement, as well as additional dermatological, photographic, and instrumental assessments, will also be considered.

Read the detailed description

This is a prospective, interventional, single-center, single-arm clinical study conducted at Meyer Children's Hospital IRCCS in Florence, Italy. The study is expected to enroll 20 pediatric participants aged 0 to 3 years.

Neonatal hyperseborrhea, commonly referred to as "cradle cap," is a frequent condition during the first months of life and may also occur in association with manifestations of seborrheic dermatitis. As part of the non-pharmacological topical management of these manifestations, cosmetic products may be used to help improve visible skin signs without exerting a pharmacological action.

TRIDERM D.S. Crema Normalizzante is a cosmetic product intended for use as a cosmetic adjunct in the presence of manifestations associated with seborrheic dermatitis. In this study, the product will be applied according to a regimen consisting of an intensive phase, with two applications per day for 10 days, followed by a maintenance phase, with two applications per day on 3 days per week for the subsequent two weeks. At the end of the product-use period, a follow-up period without product application is planned.

There will be no control group or comparator product. Assessments will be performed longitudinally within each participant by comparing the condition observed at baseline with that observed during product use and at follow-up. The overall duration of participation for each participant will be approximately 52 days. The study is exploratory and preliminary in nature and is intended to generate clinical data to support the scientific documentation and cosmetic claims related to the product.

02

Conditions studied

  • Cradle Cap
  • Seborrheic Dermatitis

Keywords

  • Neonatal hyperseborrhea
  • Infantile seborrheic dermatitis
  • Cradle cap
  • Scaling
  • Erythema
  • Pediatric dermatology
  • Cosmetic product
  • Cutaneous tolerability
  • TRIDERM D.S. Crema Normalizzante
03

In context

Dermatitis, Seborrheic

58 studies on the registry are indexed under Dermatitis, Seborrheic; 7 are open to participants now.

This study's planned enrollment of 20 is below the median of 77 across 47 interventional studies indexed under Dermatitis, Seborrheic.

Browse Dermatitis, Seborrheic studies →

Lead sponsor

ICIM International S.r.l. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 0 to 3 years.
  • Good general health.
  • Clinical diagnosis of neonatal hyperseborrhea ("cradle cap"), including possible cutaneous manifestations associated with mild-to-moderate seborrheic dermatitis.
  • No use of keratolytic, anti-inflammatory, or antifungal treatments within the 15 days prior to enrollment.
  • Written provided by the participant's parent(s) or legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Presence of other concomitant dermatological conditions that, in the Investigator's judgment, may interfere with the clinical assessment of the study.
  • Presence of seborrheic dermatitis of greater severity than that specified in the inclusion criteria.
  • Use of specific topical treatments (keratolytics, , or antifungals) on the affected areas within the 15 days prior to enrollment.
  • Participation in another clinical study within the 30 days prior to enrollment.
  • Known or suspected to one or more components of the study product.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TRIDERM D.S. Crema Normalizzante

    Participants assigned to this single experimental arm will receive the cosmetic product TRIDERM D.S. Crema Normalizzante. The product will be applied twice daily for 10 days during the intensive phase, followed by a maintenance phase consisting of twice-daily application on 3 days per week for the subsequent two weeks. After completion of the product-use period, participants will undergo a 28-day follow-up period without product application.

    Other: TRIDERM D.S. Crema Normalizzante

Interventions

  • OtherTRIDERM D.S. Crema Normalizzante

    TRIDERM D.S. Crema Normalizzante is a topical cosmetic product intended for use as a cosmetic adjunct in the presence of skin manifestations associated with seborrheic dermatitis. The product will be applied to the affected skin areas according to a two-phase regimen: an intensive phase consisting of two applications per day for 10 consecutive days, followed by a maintenance phase consisting of two applications per day on 3 days per week for the subsequent 2 weeks. After completion of the 24-day product-use period, no further product application will be performed during the 28-day follow-up period.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Investigator's Global Assessment (IGA) Score

    Clinical improvement will be assessed using the Investigator's Global Assessment (IGA), a 5-point scale ranging from 0 to 4: 0 = absent, 1 = very mild, 2 = mild, 3 = moderate, and 4 = severe. The IGA provides an overall assessment of the intensity and extent of the clinical manifestations, with particular consideration of scaling and erythema. Change in IGA score from baseline (T0) will be assessed at subsequent study visits. A decrease in the IGA score indicates clinical improvement.

    Time frame: Baseline, Day 10 (±2 days), Day 24 (±2 days), and 28 days after Day 24 (±3 days)

Secondary outcomes

  1. Change From Baseline in Erythema Score

    Erythema will be assessed by the Clinical Investigator using a 5-point semiquantitative clinical severity scale ranging from 0 to 4, where 0 indicates absence of erythema, 1 very mild erythema, 2 mild erythema, 3 moderate erythema, and 4 severe erythema. Higher scores indicate greater severity/worse outcome. Change from baseline in erythema score will be evaluated at each post-baseline study time point.

    Time frame: Baseline, Day 10 (±2 days), Day 24 (±2 days), and 28 days after Day 24 (±3 days)

  2. Change From Baseline in Scaling Score

    Scaling will be assessed by the Clinical Investigator using a 5-point semiquantitative clinical severity scale ranging from 0 to 4, where 0 indicates absence of scaling, 1 very mild scaling, 2 mild scaling, 3 moderate scaling, and 4 severe scaling. Higher scores indicate greater severity/worse outcome. Change from baseline in scaling score will be evaluated at each post-baseline study time point.

    Time frame: Baseline, Day 10 (±2 days), Day 24 (±2 days), and 28 days after Day 24 (±3 days)

  3. Percentage of Participants With at Least a 1-Point Change From Baseline in Investigator's Global Assessment (IGA) Score Toward Lower Severity

    Participants will be classified as meeting the clinical response criterion if they have at least a 1-point change from baseline in the Investigator's Global Assessment (IGA) score toward lower severity at a post-baseline study time point. The IGA is assessed by the Clinical Investigator using a 5-point semiquantitative clinical severity scale ranging from 0 to 4, where 0 indicates absence of disease signs, 1 very mild, 2 mild, 3 moderate, and 4 severe. Higher scores indicate greater severity/worse outcome. The percentage of participants meeting this criterion will be calculated at each post-baseline study time point.

    Time frame: Day 10 (±2 days), Day 24 (±2 days), and 28 days after Day 24 (±3 days)

  4. Investigator's Global Assessment of Clinical Improvement Compared With Baseline

    The Clinical Investigator will provide an overall assessment of clinical improvement compared with baseline (T0). At each post-baseline assessment, the participant's overall clinical condition will be classified as improved, unchanged, worsened, or not evaluable compared with baseline.

    Time frame: Day 10 (±2 days), Day 24 (±2 days), and 28 days after Day 24 (±3 days)

  5. Number and Percentage of Participants With Local Cutaneous Reactions

    Local cutaneous reactions will be assessed based on events observed by the Clinical Investigator or reported by the participant's parent or legal guardian during the study. Local cutaneous reactions may include erythema, irritation, pruritus, or other skin reactions at the application site. For each reaction, the description, onset date, duration, intensity, location, relationship to the study product, action taken, and outcome will be recorded in the case report form. The number and percentage of participants with at least one local cutaneous reaction will be summarized.

    Time frame: From baseline through the follow-up visit, 28 days after Day 24 (±3 days)

  6. Caregiver-Reported Responses on the Parent/Legal Guardian Product Evaluation Questionnaire

    Caregivers will complete a structured parent/legal guardian product evaluation questionnaire assessing perceived improvement in the participant's cutaneous manifestations, child comfort/tolerability, cosmetic acceptability, product use experience, overall satisfaction, and willingness to purchase or recommend the product. The perceived improvement section includes items assessed using a 5-point agreement scale ranging from 1 to 5, where 1 indicates "not at all agree" and 5 indicates "completely agree"; higher scores indicate a more favorable caregiver-reported perception of improvement. Other questionnaire items use categorical response options and will be summarized descriptively as counts and percentages by response category. No total questionnaire score is planned.

    Time frame: Day 10 (±2 days), Day 24 (±2 days), and 28 days after Day 24 (±3 days)

Other outcomes

  1. Number and Percentage of Participants by Clinical Investigator's Overall Wood's Lamp Assessment Category Compared With Baseline

    Affected skin areas will be assessed by the Clinical Investigator using a Wood's lamp. The assessment will include clinical observation of fluorescence-related findings, such as presence or absence of fluorescence, qualitative changes in fluorescence color or intensity, fluorescence distribution, and estimated extent of the fluorescent area. These observations will be used to assign one overall categorical Wood's lamp assessment compared with baseline at each post-baseline visit. Categories will be: improved, unchanged, worsened, or not evaluable. The number and percentage of participants in each category will be summarized at each post-baseline study time point.

    Time frame: Day 10 (±2 days), Day 24 (±2 days), and 28 days after Day 24 (±3 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) sharing is not planned for this study. Study results may be disseminated in aggregate form, in accordance with applicable ethical and data protection requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 6, 2026
StartEst.
Oct 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860788
Lead sponsor
ICIM International S.r.l.
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Dr. Teresa Oranges, Medical Doctor
Contact
teresa.oranges@meyer.it
+ 39 3334720816
Dr. Cesare Filippeschi, Medical Doctor
Contact
cesare.filippeschi@meyer.it

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion